{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:43:22Z","timestamp":1784335402967,"version":"3.55.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To date, the diagnoses of Parkinson syndromes are based on clinical examination. Therefore, these specific diagnoses are made, when the neuropathological process is already advanced. However, disease modification or neuroprotection, is considered to be most effective before marked neurodegeneration has occurred. In recent years, early clinical or prodromal stages of Parkinson syndromes came into focus. Moreover, subtypes of distinct diseases will allow predictions of the individual course of the diseases more precisely. Thereby, patients will be enrolled into clinical trials with more specific disease entities and endpoints. Furthermore, novel fluid and imaging biomarkers that allow biochemical diagnoses are under development. These will lead to earlier diagnoses and earlier therapy in the future as consequence. Furthermore, therapeutic approaches will take the underlying neuropathological process of neurodegenerative Parkinson syndromes more specific into account. Specifically, future therapies will target the aggregation of aggregation-prone proteins such as alpha-synuclein and tau, the degradation of pathological aggregates, and the spreading of pathological protein aggregates throughout the brain. Many of these approaches are already in (pre)clinical development. In addition, anti-inflammatory approaches are in development. Furthermore, drug-repurposing is a feasible approach to shorten the developmental process of new drugs.<\/jats:p>","DOI":"10.1007\/s00702-022-02520-6","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T14:34:04Z","timestamp":1655130844000},"page":"1133-1153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Disease modification in Parkinsonism: obstacles and ways forward"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-0121","authenticated-orcid":false,"given":"M.","family":"H\u00f6llerhage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Klietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"5","key":"2520_CR1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0000000000000641","volume":"83","author":"CH Adler","year":"2014","unstructured":"Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, Dugger BN (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83(5):406\u2013412","journal-title":"Neurology"},{"issue":"5","key":"2520_CR2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam P, Bousset L, Melki R, Otzen DE (2019) \u03b1-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150(5):522\u2013534","journal-title":"J Neurochem"},{"issue":"1","key":"2520_CR3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/mds.28785","volume":"37","author":"D Arnaldi","year":"2022","unstructured":"Arnaldi D, Mattioli P, Fam\u00e0 F, Girtler N, Brugnolo A, Pardini M, Donniaquio A, Massa F, Orso B, Raffa S, Bauckneht M, Morbelli S, Nobili F (2022) Stratification tools for disease-modifying trials in prodromal synucleinopathy. Movement Disord 37(1):52\u201361","journal-title":"Movement Disord"},{"key":"2520_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03568-8","author":"R Atarashi","year":"2022","unstructured":"Atarashi R (2022) RT-QuIC as ultrasensitive method for prion detection. Cell Tissue Res. https:\/\/doi.org\/10.1007\/s00441-021-03568-8","journal-title":"Cell Tissue Res"},{"issue":"6","key":"2520_CR5","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2113489119","volume":"119","author":"JI Ayers","year":"2022","unstructured":"Ayers JI, Lee J, Monteiro O, Woerman AL, Lazar AA, Condello C, Paras NA, Prusiner SB (2022) Different \u03b1-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Nat Acad Sci USA 119(6):e2113489119","journal-title":"Proc Nat Acad Sci USA"},{"issue":"1","key":"2520_CR6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12883-018-1184-3","volume":"18","author":"M Balzer-Geldsetzer","year":"2018","unstructured":"Balzer-Geldsetzer M, Ferreira J, Odin P, Bloem BR, Meissner WG, Lorenzl S, Wittenberg M, Dodel R, Schrag A (2018) Study protocol: care of late-stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol 18(1):185","journal-title":"BMC Neurol"},{"issue":"7","key":"2520_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.parkreldis.2010.11.008","volume":"17","author":"S Bardien","year":"2011","unstructured":"Bardien S, Lesage S, Brice A, Carr J (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson\u2019s disease. Parkinsonism Relat Disord 17(7):501\u2013508","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2520_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, Singh N, Tatsuoka C, Appleby B, Zhu X, Xu R, Haroutunian V, Zou W-Q, Ma J, Chen SG (2021) Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9(1):62","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"2520_CR9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/07853890.2013.849003","volume":"45","author":"MS Beavan","year":"2013","unstructured":"Beavan MS, Schapira AHV (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 45(8):511\u2013521","journal-title":"Ann Med"},{"issue":"6","key":"2520_CR10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","volume":"134","author":"N Bengoa-Vergniory","year":"2017","unstructured":"Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2017) Alpha-synuclein oligomers: a new hope. Acta Neuropathol 134(6):819\u2013838","journal-title":"Acta Neuropathol"},{"issue":"Pt 1","key":"2520_CR11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","volume":"132","author":"G Bensimon","year":"2009","unstructured":"Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132(Pt 1):156\u2013171","journal-title":"Brain"},{"issue":"12","key":"2520_CR12","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson\u2019s disease. Movement Disord 30(12):1600\u20131611","journal-title":"Movement Disord"},{"issue":"4","key":"2520_CR13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mds.1120","volume":"16","author":"BF Boeve","year":"2001","unstructured":"Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disord 16(4):622\u2013630","journal-title":"Movement Disord"},{"issue":"2","key":"2520_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24(2):197\u2013211","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2520_CR15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/cells10020375","volume":"10","author":"IC Br\u00e1s","year":"2021","unstructured":"Br\u00e1s IC, Outeiro TF (2021) Alpha-Synuclein: mechanisms of release and pathology progression in synucleinopathies. Cells 10(2):375","journal-title":"Cells"},{"issue":"11","key":"2520_CR16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, Palleis C, Gehmeyr M, Fietzek U, Respondek G, Sauerbeck J, Nitschmann A, Zach C, Hammes J, Barbe MT, Onur O, Jessen F, Saur D, Schroeter ML, Rumpf J-J, Rullmann M, Schildan A, Patt M, Neumaier B, Barret O, Madonia J, Russell DS, Stephens A, Roeber S, Herms J, B\u00f6tzel K, Classen J, Bartenstein P, Villemagne V, Levin J, H\u00f6glinger GU, Drzezga A, Seibyl J, Sabri O (2020) Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol 77(11):1408\u20131419","journal-title":"JAMA Neurol"},{"issue":"1","key":"2520_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-019-0522-z","volume":"11","author":"M Brendel","year":"2019","unstructured":"Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, Peters F, von Ungern-Sternberg B, Ryazanov S, Leonov A, Griesinger C, Zwergal A, Levin J, Bartenstein P, Yakushev I, Cumming P, Boening G, Ziegler S, Herms J, Giese A, Rominger A (2019) Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer\u2019s disease tau. Alzheimer\u2019s Res Ther 11(1):67","journal-title":"Alzheimer's Res Ther"},{"issue":"8","key":"2520_CR18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/NEN.0000000000000224","volume":"74","author":"J Bruch","year":"2015","unstructured":"Bruch J, Kurz C, Vasiljevic A, Nicolino M, Arzberger T, H\u00f6glinger GU (2015) Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase. J Neuropathol Exp Neurol 74(8):850\u2013857","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"2520_CR19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.15252\/emmm.201606664","volume":"9","author":"J Bruch","year":"2017","unstructured":"Bruch J, Xu H, R\u00f6sler TW, de Andrade A, Kuhn P-H, Lichtenthaler SF, Arzberger T, Winklhofer KF, M\u00fcller U, H\u00f6glinger GU (2017) PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med 9(3):371\u2013384","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2520_CR20","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","volume":"77","author":"CA Brunello","year":"2020","unstructured":"Brunello CA, Merezhko M, Uronen R-L, Huttunen HJ (2020) Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci 77(9):1721\u20131744","journal-title":"Cell Mol Life Sci"},{"key":"2520_CR21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.parkreldis.2016.01.010","volume":"24","author":"V Bruno","year":"2016","unstructured":"Bruno V, Mancini D, Ghoche R, Arshinoff R, Miyasaki JM (2016) High prevalence of physical and sexual aggression to caregivers in advanced Parkinson\u2019s disease. Experience in the Palliative Care Program. Parkinsonism Relat Disord 24:141\u2013142","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"2520_CR22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/1049909114565110","volume":"33","author":"J B\u00fckki","year":"2016","unstructured":"B\u00fckki J, N\u00fcbling G, Lorenzl S (2016) Managing advanced progressive supranuclear palsy and corticobasal degeneration in a palliative care unit: admission triggers and outcomes. Am J Hosp Palliat Care 33(5):477\u2013482","journal-title":"Am J Hosp Palliat Care"},{"issue":"4","key":"2520_CR23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.celrep.2016.09.063","volume":"17","author":"S Calafate","year":"2016","unstructured":"Calafate S, Flavin W, Verstreken P, Moechars D (2016) Loss of Bin1 promotes the propagation of tau pathology. Cell Rep 17(4):931\u2013940","journal-title":"Cell Rep"},{"issue":"10","key":"2520_CR24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14737159.2017.1368389","volume":"17","author":"N Candelise","year":"2017","unstructured":"Candelise N, Schmitz M, Da Silva Correia SM, Arora AS, Villar-Piqu\u00e9 A, Zafar S, Llorens F, Cramm M, Zerr I (2017) Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies. Expert Rev Mol Diagn 17(10):897\u2013904","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"2520_CR25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/acn3.51269","volume":"8","author":"LM Chahine","year":"2021","unstructured":"Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogl B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, Kieburtz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, Simuni T, Iranzo A (2021a) Dopamine transporter imaging predicts clinically-defined \u03b1-synucleinopathy in REM sleep behavior disorder. Anna Clin Transl Neurol 8(1):201\u2013212","journal-title":"Anna Clin Transl Neurol"},{"issue":"8","key":"2520_CR26","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1007\/s00415-021-10443-7","volume":"268","author":"LM Chahine","year":"2021","unstructured":"Chahine LM, Feldman R, Althouse A, Torsney B, Alzyoud L, Mantri S, Edison B, Albert S, Daeschler M, Kopil C, Marras C (2021b) Contribution of neuropsychiatric symptoms in Parkinson\u2019s disease to different domains of caregiver burden. J Neurol 268(8):2961\u20132972","journal-title":"J Neurol"},{"issue":"12","key":"2520_CR27","doi-asserted-by":"crossref","first-page":"10814","DOI":"10.1074\/jbc.M110.132514","volume":"286","author":"V Choubey","year":"2011","unstructured":"Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A (2011) Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 286(12):10814\u201310824","journal-title":"J Biol Chem"},{"issue":"1","key":"2520_CR28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s41999-021-00548-7","volume":"13","author":"D Churm","year":"2022","unstructured":"Churm D, Dickinson C, Robinson L, Paes P, Cronin T, Walker R (2022) Understanding how people with Parkinson\u2019s disease and their relatives approach advance care planning. Eur Geriatr Med 13(1):109\u2013117","journal-title":"Eur Geriatr Med"},{"key":"2520_CR29","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/519816","volume":"2014","author":"R Ciurleo","year":"2014","unstructured":"Ciurleo R, Di Lorenzo G, Bramanti P, Marino S (2014) Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson\u2019s disease? Biomed Res Int 2014:519816","journal-title":"Biomed Res Int"},{"issue":"8","key":"2520_CR30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam T, Boxer AL, Golbe LI, H\u00f6glinger GU, Morris HR, Litvan I, Lang AE, Corvol J-C, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O\u2019Gorman J, Haeberlein SB (2021) Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med 27(8):1451\u20131457","journal-title":"Nat Med"},{"issue":"10","key":"2520_CR31","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/jpm11101030","volume":"11","author":"M Dehestani","year":"2021","unstructured":"Dehestani M, Liu H, Gasser T (2021) Polygenic risk scores contribute to personalized medicine of Parkinson\u2019s Disease. J Personalized Med 11(10):1030","journal-title":"J Personalized Med"},{"issue":"Suppl 1","key":"2520_CR32","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1):S30\u2013S33","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 2","key":"2520_CR33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00062-015-0428-5","volume":"25","author":"X-Q Ding","year":"2015","unstructured":"Ding X-Q, Lanfermann H (2015) Whole brain 1H-Spectroscopy: a developing technique for advanced analysis of cerebral metabolism. Clin Neuroradiol 25(Suppl 2):245\u2013250","journal-title":"Clin Neuroradiol"},{"issue":"1","key":"2520_CR34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mds.22732","volume":"25","author":"R Dodel","year":"2010","unstructured":"Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-D\u00f6ring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, K\u00f6llensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, B\u00f6ttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and (11)C (R)-PK11195 PET (MEMSA-trial). Movement Disord 25(1):97\u2013107","journal-title":"Movement Disord"},{"issue":"3","key":"2520_CR35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JPD-202489","volume":"11","author":"K Doppler","year":"2021","unstructured":"Doppler K (2021) Detection of dermal alpha-synuclein deposits as a biomarker for Parkinson\u2019s Disease. J Parkinsons Dis 11(3):937\u2013947","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"2520_CR36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","volume":"133","author":"K Doppler","year":"2017","unstructured":"Doppler K, Jentschke H-M, Schulmeyer L, Vadasz D, Janzen A, Luster M, H\u00f6ffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson\u2019s disease. Acta Neuropathol 133(4):535\u2013545","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2520_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/brainsci12010089","volume":"12","author":"H von Eichel","year":"2022","unstructured":"von Eichel H, Heine J, Wegner F, Rogozinski S, Stiel S, Groh A, Krey L, H\u00f6glinger GU, Klietz M (2022) Neuropsychiatric symptoms in Parkinson\u2019s disease patients are associated with reduced health-related quality of life and increased caregiver burden. Brain Sci 12(1):89","journal-title":"Brain Sci"},{"issue":"9","key":"2520_CR38","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114745","volume":"13","author":"M Emmenegger","year":"2021","unstructured":"Emmenegger M, de Cecco E, Hruska-Plochan M, Eninger T, Schneider MM, Barth M, Tantardini E, de Rossi P, Bacioglu M, Langston RG, Kaganovich A, Bengoa-Vergniory N, Gonzalez-Guerra A, Avar M, Heinzer D, Reimann R, H\u00e4sler LM, Herling TW, Matharu NS, Landeck N, Luk K, Melki R, Kahle PJ, Hornemann S, Knowles TPJ, Cookson MR, Polymenidou M, Jucker M, Aguzzi A (2021) LAG3 is not expressed in human and murine neurons and does not modulate \u03b1-synucleinopathies. EMBO Mol Med 13(9):e14745","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2520_CR39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249\u2013263","journal-title":"N Engl J Med"},{"issue":"Pt 5","key":"2520_CR40","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ (1991) Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283\u20132301","journal-title":"Brain"},{"key":"2520_CR41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fnins.2016.00099","volume":"10","author":"L Fellner","year":"2016","unstructured":"Fellner L, Kuzdas-Wood D, Levin J, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2016) Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy. Front Neurosci 10:99","journal-title":"Front Neurosci"},{"issue":"1","key":"2520_CR42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/cr.2013.168","volume":"24","author":"Y Feng","year":"2014","unstructured":"Feng Y, He D, Yao Z, Klionsky DJ (2014) The machinery of macroautophagy. Cell Res 24(1):24\u201341","journal-title":"Cell Res"},{"issue":"7","key":"2520_CR43","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"S-M Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad S-M, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain 140(7):1959\u20131976","journal-title":"Brain"},{"key":"2520_CR44","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.718188","volume":"15","author":"L Fernandes","year":"2021","unstructured":"Fernandes L, Cardim-Pires TR, Foguel D, Palhano FL (2021) Green tea polyphenol epigallocatechin-gallate in amyloid aggregation and neurodegenerative diseases. Front Neurosci 15:718188","journal-title":"Front Neurosci"},{"issue":"6","key":"2520_CR45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.neuron.2022.01.017","volume":"110","author":"A Fleming","year":"2022","unstructured":"Fleming A, Bourdenx M, Fujimaki M, Karabiyik C, Krause GJ, Lopez A, Mart\u00edn-Segura A, Puri C, Scrivo A, Skidmore J, Son SM, Stamatakou E, Wrobel L, Zhu Y, Cuervo AM, Rubinsztein DC (2022) The different autophagy degradation pathways and neurodegeneration. Neuron 110(6):935\u2013966","journal-title":"Neuron"},{"key":"2520_CR46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2021.05.001","volume":"87","author":"J Folke","year":"2021","unstructured":"Folke J, Rydbirk R, L\u00f8kkegaard A, Hejl A-M, Winge K, Starhof C, Salvesen L, Pedersen L\u00d8, Aznar S, Pakkenberg B, Brudek T (2021) Cerebrospinal fluid and plasma distribution of anti-\u03b1-synuclein IgMs and IgGs in multiple system atrophy and Parkinson\u2019s disease. Parkinsonism Relat Disord 87:98\u2013104","journal-title":"Parkinsonism Relat Disord"},{"key":"2520_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104813","volume":"139","author":"A Foubert-Samier","year":"2020","unstructured":"Foubert-Samier A, Pavy-Le Traon A, Guillet F, Le-Goff M, Helmer C, Tison F, Rascol O, Proust-Lima C, Meissner WG (2020) Disease progression and prognostic factors in multiple system atrophy: a prospective cohort study. Neurobiol Dis 139:104813","journal-title":"Neurobiol Dis"},{"issue":"1","key":"2520_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-018-0497-5","volume":"32","author":"AJ Fowler","year":"2018","unstructured":"Fowler AJ, Moussa CE-H (2018) Activating autophagy as a therapeutic strategy for Parkinson\u2019s disease. CNS Drugs 32(1):1\u201311","journal-title":"CNS Drugs"},{"issue":"9","key":"2520_CR49","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/acn3.51065","volume":"7","author":"A Frank","year":"2020","unstructured":"Frank A, Peikert K, Linn J, Brandt MD, Hermann A (2020) MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome. Ann Clin Transl Neurol 7(9):1702\u20131707","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"2520_CR50","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41419-018-0816-2","volume":"9","author":"N Fussi","year":"2018","unstructured":"Fussi N, H\u00f6llerhage M, Chakroun T, Nyk\u00e4nen N-P, R\u00f6sler TW, Koeglsperger T, Wurst W, Behrends C, H\u00f6glinger GU (2018) Exosomal secretion of \u03b1-synuclein as protective mechanism after upstream blockage of macroautophagy. Cell Death Dis 9(7):757","journal-title":"Cell Death Dis"},{"issue":"4","key":"2520_CR51","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/mds.23499","volume":"26","author":"A Gaenslen","year":"2011","unstructured":"Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients\u2019 perception of prodromal symptoms before the initial diagnosis of Parkinson\u2019s disease. Movement Disord 26(4):653\u2013658","journal-title":"Movement Disord"},{"issue":"8","key":"2520_CR52","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2520_CR53","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12909-021-02964-6","volume":"21","author":"D Gatsios","year":"2021","unstructured":"Gatsios D, Antonini A, Gentile G, Konitsiotis S, Fotiadis D, Nixina I, Taba P, Weck C, Lorenzl S, Lex KM, Paal P (2021) Education on palliative care for Parkinson patients: development of the \u201cBest care for people with late-stage Parkinson\u2019s disease\u201d curriculum toolkit. BMC Med Educ 21(1):538","journal-title":"BMC Med Educ"},{"issue":"4","key":"2520_CR54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.30773\/pi.2019.02.20","volume":"16","author":"F Gen\u00e7","year":"2019","unstructured":"Gen\u00e7 F, Yuksel B, Tokuc FEU (2019) Caregiver burden and quality of life in early and late stages of idiopathic Parkinson\u2019s disease. Psychiatry Investig 16(4):285\u2013291","journal-title":"Psychiatry Investig"},{"issue":"17","key":"2520_CR55","doi-asserted-by":"crossref","first-page":"e1828","DOI":"10.1212\/WNL.0000000000009372","volume":"94","author":"G Giannini","year":"2020","unstructured":"Giannini G, Mastrangelo V, Provini F, Droghini A, Cecere A, Barletta G, Mignani F, Guaraldi P, Cortelli P, Calandra-Buonaura G (2020) Progression and prognosis in multiple system atrophy presenting with REM behavior disorder. Neurology 94(17):e1828\u2013e1834","journal-title":"Neurology"},{"issue":"2","key":"2520_CR56","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JPD-212904","volume":"12","author":"MP Giannoccaro","year":"2022","unstructured":"Giannoccaro MP, Avoni P, Rizzo G, Incensi A, Infante R, Donadio V, Liguori R (2022) Presence of skin \u03b1-Synuclein deposits discriminates Parkinson\u2019s disease from progressive supranuclear palsy and corticobasal syndrome. J Parkinsons Dis 12(2):585\u2013591","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2520_CR57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","volume":"9","author":"M Goedert","year":"2013","unstructured":"Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9(1):13\u201324","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2520_CR58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00702-020-02276-x","volume":"128","author":"S Greten","year":"2021","unstructured":"Greten S, M\u00fcller-Funogea JI, Wegner F, H\u00f6glinger GU, Simon N, Junius-Walker U, Gerbel S, Krause O, Klietz M (2021) Drug safety profiles in geriatric patients with Parkinson\u2019s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Trans (vienna, Austria: 1996) 128(1):49\u201360","journal-title":"J Neural Trans (vienna, Austria: 1996)"},{"issue":"8","key":"2520_CR59","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/mds.27666","volume":"34","author":"M-J Grimm","year":"2019","unstructured":"Grimm M-J, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol J-C, Lang AE, Rowe JB, H\u00f6glinger GU (2019) How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disord 34(8):1228\u20131232","journal-title":"Movement Disord"},{"issue":"12","key":"2520_CR60","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/mds.28263","volume":"35","author":"M-J Grimm","year":"2020","unstructured":"Grimm M-J, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Meissner WG, Nilsson C, Piot I, Compta Y, Rowe JB, H\u00f6glinger GU (2020) Clinical conditions \u201csuggestive of progressive supranuclear palsy\u201d-diagnostic performance. Movement Disord 35(12):2301\u20132313","journal-title":"Movement Disord"},{"issue":"5","key":"2520_CR61","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.28470","volume":"36","author":"M-T Gr\u00f6tsch","year":"2021","unstructured":"Gr\u00f6tsch M-T, Respondek G, Colosimo C, Compta Y, Corvol JC, Ferreira J, Huber MK, Klietz M, Krey LFM, Levin J, Jecmenica-Lukic M, Mac\u00edas-Garc\u00eda D, Meissner WG, Mir P, Morris H, Nilsson C, Rowe JB, Seppi K, Stamelou M, van Swieten JC, Wenning G, Del Ser T, Golbe LI, H\u00f6glinger GU (2021) A modified progressive supranuclear palsy rating scale. Movement Disord 36(5):1203\u20131215","journal-title":"Movement Disord"},{"issue":"7","key":"2520_CR62","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jamda.2016.03.004","volume":"17","author":"D Gr\u00fcn","year":"2016","unstructured":"Gr\u00fcn D, Pieri V, Vaillant M, Diederich NJ (2016) Contributory factors to caregiver burden in Parkinson disease. J Am Med Dir Assoc 17(7):626\u2013632","journal-title":"J Am Med Dir Assoc"},{"key":"2520_CR63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.parkreldis.2021.01.015","volume":"84","author":"M Guasp","year":"2021","unstructured":"Guasp M, Molina-Porcel L, Painous C, Caballol N, Camara A, Perez-Soriano A, S\u00e1nchez-G\u00f3mez A, Garrido A, Mu\u00f1oz E, Marti MJ, Valldeoriola F, Grau O, Gelp\u00ed E, Respondek G, H\u00f6glinger GH, Compta Y (2021) Association of PSP phenotypes with survival: a brain-bank study. Parkinsonism Relat Disord 84:77\u201381","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"2520_CR64","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/brainsci11060822","volume":"11","author":"J Heine","year":"2021","unstructured":"Heine J, von Eichel H, Staege S, H\u00f6glinger GU, Wegner F, Klietz M (2021) Relationship satisfaction in people with Parkinson\u2019s disease and their caregivers: a cross-sectional observational study. Brain Sci 11(6):822","journal-title":"Brain Sci"},{"issue":"10","key":"2520_CR65","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.27802","volume":"34","author":"S Heinzel","year":"2019","unstructured":"Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB (2019) Update of the MDS research criteria for prodromal Parkinson\u2019s disease. Movement Disord 34(10):1464\u20131470","journal-title":"Movement Disord"},{"key":"2520_CR66","first-page":"6920943","volume":"2020","author":"C Hellqvist","year":"2020","unstructured":"Hellqvist C, Berter\u00f6 C, Dizdar N, Sund-Levander M, Hagell P (2020) Self-management education for persons with parkinson\u2019s disease and their care partners: a quasi-experimental case-control study in clinical practice. Parkinson\u2019s Dis 2020:6920943","journal-title":"Parkinson's Dis"},{"issue":"19\u201320","key":"2520_CR67","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1111\/jocn.14522","volume":"27","author":"C Hellqvist","year":"2018","unstructured":"Hellqvist C, Dizdar N, Hagell P, Berter\u00f6 C, Sund-Levander M (2018) Improving self-management for persons with Parkinson\u2019s disease through education focusing on management of daily life: patients\u2019 and relatives\u2019 experience of the Swedish National Parkinson School. J Clin Nurs 27(19\u201320):3719\u20133728","journal-title":"J Clin Nurs"},{"issue":"2","key":"2520_CR68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2019","unstructured":"Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2019) Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disord 34(2):255\u2013263","journal-title":"Movement Disord"},{"issue":"3","key":"2520_CR69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(20)30477-4","volume":"20","author":"P Hermann","year":"2021","unstructured":"Hermann P, Appleby B, Brandel J-P, Caughey B, Collins S, Geschwind MD, Green A, Ha\u00efk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P, Pocchiari M, Satoh K, Zanusso G, Zerr I (2021) Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 20(3):235\u2013246","journal-title":"Lancet Neurol"},{"issue":"3","key":"2520_CR70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon H-K, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H, Ahmed A, Aiba I, Albanese A, Bertram K, Bordelon Y, Bower J, Brosch J, Claassen D, Colosimo C, Corvol J-C, Cudia P, Daniele A, Defebvre L, Driver-Dunckley E, Duquette A, Eleopra R, Eusebio A, Fung V, Geldmacher D, Golbe L, Grandas F, Hall D, Hatano T, Honig L, Hui J, Kerwin D, Kikuchi A, Kimber T, Kimura T, Kumar R, Ljubenkov P, Lorenzl S, Ludolph A, Mari Z, McFarland N, Meissner W, Mir Rivera P, Mochizuki H, Morgan J, Munhoz R, Nishikawa N, O\u2019Sullivan J, Oeda T, Oizumi H, Onodera O, Ory-Magne F, Peckham E, Postuma R, Quattrone A, Quinn J, Ruggieri S, Sarna J, Schulz PE, Slevin J, Tagliati M, Wile D, Wszolek Z, Xie T, Zesiewicz T (2021) Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 20(3):182\u2013192","journal-title":"Lancet Neurol"},{"issue":"7","key":"2520_CR71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ng.859","volume":"43","author":"GU H\u00f6glinger","year":"2011","unstructured":"H\u00f6glinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang L-S, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu C-E, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, M\u00fcller U, Schellenberg GD (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43(7):699\u2013705","journal-title":"Nat Genet"},{"issue":"6","key":"2520_CR72","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, M\u00fcller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol J-C, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Movement Disord 32(6):853\u2013864","journal-title":"Movement Disord"},{"key":"2520_CR73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuropharm.2019.01.023","volume":"149","author":"M H\u00f6llerhage","year":"2019","unstructured":"H\u00f6llerhage M, Fussi N, R\u00f6sler TW, Wurst W, Behrends C, H\u00f6glinger GU (2019) Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons. Neuropharmacology 149:13\u201326","journal-title":"Neuropharmacology"},{"issue":"7","key":"2520_CR74","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.neurobiolaging.2014.01.027","volume":"35","author":"M H\u00f6llerhage","year":"2014","unstructured":"H\u00f6llerhage M, Goebel JN, de Andrade A, Hildebrandt T, Dolga A, Culmsee C, Oertel WH, Hengerer B, H\u00f6glinger GU (2014) Trifluoperazine rescues human dopaminergic cells from wild-type \u03b1-synuclein-induced toxicity. Neurobiol Aging 35(7):1700\u20131711","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2520_CR75","doi-asserted-by":"crossref","first-page":"11469","DOI":"10.1038\/s41598-017-11664-5","volume":"7","author":"M H\u00f6llerhage","year":"2017","unstructured":"H\u00f6llerhage M, Moebius C, Melms J, Chiu W-H, Goebel JN, Chakroun T, Koeglsperger T, Oertel WH, R\u00f6sler TW, Bickle M, H\u00f6glinger GU (2017) Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep 7(1):11469","journal-title":"Sci Rep"},{"issue":"33","key":"2520_CR76","doi-asserted-by":"crossref","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","volume":"110","author":"BB Holmes","year":"2013","unstructured":"Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110(33):E3138\u2013E3147","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2520_CR77","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/mdc3.12968","volume":"7","author":"ALAJ Hommel","year":"2020","unstructured":"Hommel ALAJ, Meinders MJ, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, Laurens B, Spampinato U, Meissner W, Rosqvist K, Timpka J, Odin P, Wittenberg M, Bloem PhD BR, Koopmans RT, Schrag A (2020) The prevalence and determinants of neuropsychiatric symptoms in late-stage Parkinsonism. Movement Disord Clin Pract 7(5):531\u2013542","journal-title":"Movement Disord Clin Pract"},{"key":"2520_CR78","doi-asserted-by":"crossref","unstructured":"Hopfner F, Tietz AK, Ruf V, Ross OA, Koga S, Dickson D, Aguzzi A, Attems J, Beach T, Beller A, van Deerlin V, Desplats P, Deuschl G, Duyckaerts C, Ellinghaus D, Evsyukov V, Flanagan ME, Franke A, Frosch MP, Gearing M, Gelpi E, Ghetti B, Glass JD, Grinberg LT, Halliday G, Helbig I, H\u00f6llerhage M, Huitinga I, Irwin DJ, Keene DC, Kovacs GG, Lee EB, Levin J, Mart\u00ed MJ, Mackenzie I, McKeith I, McLean C, Mollenhauer B, Neumann M, Newell KL, Pantelyat A, Pendziwiat M, Peters A, Porcel LM, Rabano A, Mat\u011bj R, Rajput A, Rajput A, Reimann R, Scott WK, Seeley W, Selvackadunco S, Simuni T, Stadelmann C, Svenningsson P, Thomas A, Trenkwalder C, Troakes C, Trojanowski JQ, White CL, Xie T, Ximelis T, Yebenes J, M\u00fcller U, Schellenberg GD, Herms J, Kuhlenb\u00e4umer G, H\u00f6glinger G (2022) Common variants near ZIC1 and ZIC4 in autopsy-confirmed Multiple System Atrophy. Movement Disord (in press)","DOI":"10.1002\/mds.29164"},{"issue":"3","key":"2520_CR79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, Riha RL, Green AJE (2021) Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 20(3):203\u2013212","journal-title":"Lancet Neurol"},{"issue":"8","key":"2520_CR80","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-021-01465-9","volume":"27","author":"E Jabbari","year":"2021","unstructured":"Jabbari E, Duff KE (2021) Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nat Med 27(8):1341\u20131342","journal-title":"Nat Med"},{"issue":"10","key":"2520_CR81","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/jnnp-2017-315857","volume":"88","author":"E Jabbari","year":"2017","unstructured":"Jabbari E, Zetterberg H, Morris HR (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry 88(10):883\u2013888","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"2520_CR82","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.3390\/ijms22158338","volume":"22","author":"A Jan","year":"2021","unstructured":"Jan A, Gon\u00e7alves NP, Vaegter CB, Jensen PH, Ferreira N (2021) The prion-like spreading of alpha-synuclein in Parkinson\u2019s disease: update on models and hypotheses. Int J Mol Sci 22(15):8338","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2520_CR83","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I (1990) Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529\u20131534","journal-title":"Neurology"},{"key":"2520_CR01","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/brainsci12060749","volume":"12","author":"I Jensen","year":"2022","unstructured":"Jensen I, Bretschneider A, Stiel S, Wegner F, H\u00f6glinger GU, Klietz M (2022) Analysis of Parkinson\u2019s disease outpatient counselling for advance directive creation: a cross-sectional questionnaire-based survey of german general practitioners and neurologists. Brain Sci 12:749","journal-title":"Brain Sci"},{"issue":"11","key":"2520_CR84","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/brainsci11111470","volume":"11","author":"I Jensen","year":"2021","unstructured":"Jensen I, Lescher E, Stiel S, Wegner F, H\u00f6glinger G, Klietz M (2021) Analysis of transition of patients with Parkinson\u2019s disease into institutional care: a retrospective pilot study. Brain Sci 11(11):1470","journal-title":"Brain Sci"},{"issue":"11","key":"2520_CR85","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/mds.28591","volume":"36","author":"C Jiang","year":"2021","unstructured":"Jiang C, Hopfner F, Berg D, Hu MT, Pilotto A, Borroni B, Davis JJ, Tofaris GK (2021) Validation of \u03b1-Synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of Parkinsonian syndromes. Movement Disord 36(11):2663\u20132669","journal-title":"Movement Disord"},{"issue":"7","key":"2520_CR86","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang C, Hopfner F, Katsikoudi A, Hein R, Catli C, Evetts S, Huang Y, Wang H, Ryder JW, Kuhlenbaeumer G, Deuschl G, Padovani A, Berg D, Borroni B, Hu MT, Davis JJ, Tofaris GK (2020) Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 91(7):720\u2013729","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"2520_CR87","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1111\/febs.15617","volume":"288","author":"HE Johnston","year":"2021","unstructured":"Johnston HE, Samant RS (2021) Alternative systems for misfolded protein clearance: life beyond the proteasome. FEBS J 288(15):4464\u20134487","journal-title":"FEBS J"},{"issue":"10","key":"2520_CR88","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","volume":"21","author":"M Jucker","year":"2018","unstructured":"Jucker M, Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21(10):1341\u20131349","journal-title":"Nat Neurosci"},{"issue":"10","key":"2520_CR89","first-page":"1277","volume":"70","author":"J-H Kang","year":"2013","unstructured":"Kang J-H, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Walig\u00f3rska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM (2013) Association of cerebrospinal fluid \u03b2-amyloid 1\u201342, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277\u20131287","journal-title":"JAMA Neurol"},{"issue":"2","key":"2520_CR90","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/jcm9020449","volume":"9","author":"M Klietz","year":"2020","unstructured":"Klietz M, Berndt JM, Wegner F, Schneider N, H\u00f6glinger GU, Eggers C, Stiel S (2020a) Consensus-based recommendations for advance directives of people with Parkinson\u2019s Disease in regard to typical complications by German movement disorder specialists. J Clin Med 9(2):449","journal-title":"J Clin Med"},{"key":"2520_CR91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3389\/fneur.2019.00777","volume":"10","author":"M Klietz","year":"2019","unstructured":"Klietz M, Bronzlik P, N\u00f6sel P, Wegner F, Dressler DW, Dadak M, Maudsley AA, Sheriff S, Lanfermann H, Ding X-Q (2019a) Altered neurometabolic profile in early Parkinson\u2019s disease: a study with short echo-time whole brain MR spectroscopic imaging. Front Neurol 10:777","journal-title":"Front Neurol"},{"key":"2520_CR92","first-page":"9990679","volume":"2021","author":"M Klietz","year":"2021","unstructured":"Klietz M, Eichel HV, Staege S, Kutschenko A, Respondek G, Huber MK, Greten S, H\u00f6glinger GU, Wegner F (2021a) Validation of the Parkinson\u2019s disease caregiver burden questionnaire in progressive supranuclear palsy. Parkinson\u2019s Dis 2021:9990679","journal-title":"Parkinson's Dis"},{"issue":"3","key":"2520_CR93","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/brainsci11030295","volume":"11","author":"M Klietz","year":"2021","unstructured":"Klietz M, von Eichel H, Schnur T, Staege S, H\u00f6glinger GU, Wegner F, Stiel S (2021b) One year trajectory of caregiver burden in Parkinson\u2019s disease and analysis of gender-specific aspects. Brain Sci 11(3):295","journal-title":"Brain Sci"},{"key":"2520_CR94","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.763331","volume":"13","author":"M Klietz","year":"2021","unstructured":"Klietz M, Elaman MH, Mahmoudi N, N\u00f6sel P, Ahlswede M, Wegner F, H\u00f6glinger GU, Lanfermann H, Ding X-Q (2021c) Cerebral microstructural alterations in patients with early Parkinson\u2019s disease detected with quantitative magnetic resonance measurements. Front Aging Neurosci 13:763331","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"2520_CR95","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40266-019-00654-z","volume":"36","author":"M Klietz","year":"2019","unstructured":"Klietz M, Greten S, Wegner F, H\u00f6glinger GU (2019b) Safety and tolerability of pharmacotherapies for Parkinson\u2019s disease in geriatric patients. Drugs Aging 36(6):511\u2013530","journal-title":"Drugs Aging"},{"key":"2520_CR96","first-page":"2107821","volume":"2019","author":"M Klietz","year":"2019","unstructured":"Klietz M, \u00d6calan \u00d6, Schneider N, Dressler D, Stiel S, Wegner F (2019c) Advance directives of german people with Parkinson\u2019s disease are unspecific in regard to typical complications. Parkinson\u2019s Dis 2019:2107821","journal-title":"Parkinson's Dis"},{"issue":"12","key":"2520_CR97","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1017\/S1041610219000206","volume":"31","author":"M Klietz","year":"2019","unstructured":"Klietz M, Rippena L, Lange F, Tulke A, Paracka L, Dressler D, Wegner F (2019d) Validating the Parkinson\u2019s disease caregiver burden questionnaire (PDCB) in German caregivers of advanced Parkinson\u2019s disease patients. Int Psychogeriatr 31(12):1791\u20131800","journal-title":"Int Psychogeriatr"},{"key":"2520_CR98","first-page":"5184084","volume":"2020","author":"M Klietz","year":"2020","unstructured":"Klietz M, Schnur T, Drexel S, Lange F, Tulke A, Rippena L, Paracka L, Dressler D, H\u00f6glinger GU, Wegner F (2020b) Association of motor and cognitive symptoms with health-related quality of life and caregiver burden in a German cohort of advanced Parkinson\u2019s disease patients. Parkinson\u2019s Dis 2020:5184084","journal-title":"Parkinson's Dis"},{"issue":"6","key":"2520_CR99","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/brainsci10060401","volume":"10","author":"M Klietz","year":"2020","unstructured":"Klietz M, Schnur T, Drexel SC, Lange F, Paracka L, Huber MK, Dressler D, H\u00f6glinger GU, Wegner F (2020c) Alexithymia is associated with reduced quality of life and increased caregiver burden in Parkinson\u2019s disease. Brain Sci 10(6):401","journal-title":"Brain Sci"},{"key":"2520_CR100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fneur.2018.00120","volume":"9","author":"M Klietz","year":"2018","unstructured":"Klietz M, Tulke A, M\u00fcschen LH, Paracka L, Schrader C, Dressler DW, Wegner F (2018) Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson\u2019s disease patients. Front Neurol 9:120","journal-title":"Front Neurol"},{"issue":"2","key":"2520_CR101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/jnnp-2017-315813","volume":"89","author":"S Koga","year":"2018","unstructured":"Koga S, Dickson DW (2018) Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry 89(2):175\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2520_CR102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW (2021) Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener 16(1):83","journal-title":"Mol Neurodegener"},{"issue":"9","key":"2520_CR103","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/ph14090847","volume":"14","author":"\u0160 Korat","year":"2021","unstructured":"Korat \u0160, Bidesi NSR, Bonanno F, Di Nanni A, Ho\u00e0ng ANN, Herfert K, Maurer A, Battisti UM, Bowden GD, Thonon D, Vugts D, Windhorst AD, Herth MM (2021) Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals (basel, Switzerland) 14(9):847","journal-title":"Pharmaceuticals (basel, Switzerland)"},{"issue":"2","key":"2520_CR104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C, McMillan CT, Gelpi E, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Roeber S, Xie SX, Lee VM-Y, Trojanowski JQ, H\u00f6glinger GU (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140(2):99\u2013119","journal-title":"Acta Neuropathol"},{"issue":"23","key":"2520_CR105","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.3390\/jcm10235618","volume":"10","author":"L Krey","year":"2021","unstructured":"Krey L, Lange P, Tran AT, Greten S, H\u00f6glinger GU, Wegner F, Krause O, Klietz M (2021) Patient safety in a box: implementation and evaluation of the emergency box in geriatric and Parkinson patients. J Clin Med 10(23):5618","journal-title":"J Clin Med"},{"key":"2520_CR106","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.637176","volume":"12","author":"MJ Kwasny","year":"2021","unstructured":"Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, H\u00f6glinger GU (2021) Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176","journal-title":"Front Neurol"},{"issue":"2","key":"2520_CR107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/biom12020329","volume":"12","author":"EH Kwon","year":"2022","unstructured":"Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, T\u00f6nges L (2022) Update on CSF biomarkers in Parkinson\u2019s disease. Biomolecules 12(2):329","journal-title":"Biomolecules"},{"issue":"1","key":"2520_CR108","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40035-020-00217-y","volume":"9","author":"M Lemos","year":"2020","unstructured":"Lemos M, Venezia S, Refolo V, Heras-Garvin A, Schmidhuber S, Giese A, Leonov A, Ryazanov S, Griesinger C, Galabova G, Staffler G, Wenning GK, Stefanova N (2020) Targeting \u03b1-synuclein by PD03 AFFITOPE\u00ae and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Transl Neurodegeneration 9(1):38","journal-title":"Transl Neurodegeneration"},{"issue":"5","key":"2520_CR109","first-page":"61","volume":"113","author":"J Levin","year":"2016","unstructured":"Levin J, Kurz A, Arzberger T, Giese A, H\u00f6glinger GU (2016a) The Differential diagnosis and treatment of atypical Parkinsonism. Deutsches Arzteblatt Int 113(5):61\u201369","journal-title":"Deutsches Arzteblatt Int"},{"issue":"8","key":"2520_CR110","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","volume":"18","author":"J Levin","year":"2019","unstructured":"Levin J, Maa\u00df S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, S\u00fcdmeyer M, Eggert K, Mollenhauer B, Lipp A, L\u00f6hle M, Classen J, M\u00fcnchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, B\u00f6tzel K, Ertl-Wagner B, Huppertz H-J, Ricard I, H\u00f6glinger GU, Andr\u00e9 E, Blankenstein C, Canelo M, D\u00fcring M, Ebentheuer J, Fricke C, Gerbes A, Groiss S, Gruber D, Hartmann C, Kirchner T, Kroneberg D, Kunz M, Lorenzl S, Moldovan A, Noda A, Pape H, Respondek G, Sch\u00e4ffer E, Schneider M, Schnitzler A, Schulz-Schaeffer W, Schwarz J, Skowronek C, Storch A, Tadic V, Vad\u00e1sz D, Zimmermann B (2019) Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 18(8):724\u2013735","journal-title":"Lancet Neurol"},{"issue":"4","key":"2520_CR111","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00702-016-1507-8","volume":"123","author":"J Levin","year":"2016","unstructured":"Levin J, Maa\u00df S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G, Giese A, B\u00f6tzel K, H\u00f6glinger G (2016b) The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transmission (vienna, Austria: 1996) 123(4):439\u2013445","journal-title":"J Neural Transmission (vienna, Austria: 1996)"},{"issue":"5","key":"2520_CR112","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","volume":"127","author":"J Levin","year":"2014","unstructured":"Levin J, Schmidt F, Boehm C, Prix C, B\u00f6tzel K, Ryazanov S, Leonov A, Griesinger C, Giese A (2014) The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 127(5):779\u2013780","journal-title":"Acta Neuropathol"},{"issue":"Suppl 1","key":"2520_CR113","first-page":"S41","volume":"84","author":"P Lingor","year":"2016","unstructured":"Lingor P, Csoti I, Koschel J, Schrader C, Winkler C, Wolz M, Reichmann H (2016) Der geriatrische Parkinson-Patient - eine neurologische Herausforderung (The Geriatric Patient with Parkinson\u2019s Disease - a Neurological Challenge). Fortschr Neurol Psychiatr 84(Suppl 1):S41\u2013S47","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"1","key":"2520_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1\u20139","journal-title":"Neurology"},{"issue":"4","key":"2520_CR115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ane.12546","volume":"134","author":"G Lopez","year":"2016","unstructured":"Lopez G, Bayulkem K, Hallett M (2016) Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants. Acta Neurol Scand 134(4):242\u2013249","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"2520_CR116","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(15)00058-7","volume":"14","author":"PA Low","year":"2015","unstructured":"Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710\u2013719","journal-title":"Lancet Neurol"},{"issue":"22","key":"2520_CR117","doi-asserted-by":"crossref","first-page":"e2571","DOI":"10.1212\/WNL.0000000000007552","volume":"92","author":"HD Lum","year":"2019","unstructured":"Lum HD, Jordan SR, Brungardt A, Ayele R, Katz M, Miyasaki JM, Hall A, Jones J, Kluger B (2019) Framing advance care planning in Parkinson disease: patient and care partner perspectives. Neurology 92(22):e2571\u2013e2579","journal-title":"Neurology"},{"issue":"13","key":"2520_CR118","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/mds.25898","volume":"29","author":"AD Macleod","year":"2014","unstructured":"Macleod AD, Taylor KSM, Counsell CE (2014) Mortality in Parkinson\u2019s disease: a systematic review and meta-analysis. Movement Disord 29(13):1615\u20131622","journal-title":"Movement Disord"},{"issue":"8","key":"2520_CR119","first-page":"804","volume":"11","author":"L Magistrelli","year":"2021","unstructured":"Magistrelli L, Contaldi E, Comi C (2021) The Impact of SNCA variations and its product alpha-synuclein on non-motor features of Parkinson\u2019s disease. Life (Basel, Switzerland) 11(8):804","journal-title":"Life (Basel, Switzerland)"},{"issue":"5","key":"2520_CR120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000314495","volume":"7","author":"P Mahlknecht","year":"2010","unstructured":"Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K (2010) Significance of MRI in diagnosis and differential diagnosis of Parkinson\u2019s disease. Neurodegener Dis 7(5):300\u2013318","journal-title":"Neurodegener Dis"},{"issue":"6307","key":"2520_CR121","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X Mao","year":"2016","unstructured":"Mao X, Ou MT, Karuppagounder SS, Kam T-I, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin J-H, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gon\u00e7alves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DAA, Dawson VL, Ko HS, Dawson TM (2016) Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (new York, NY) 353(6307):3374","journal-title":"Science (new York, NY)"},{"issue":"4","key":"2520_CR122","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s13311-020-00894-7","volume":"17","author":"C Marras","year":"2020","unstructured":"Marras C, Chaudhuri KR, Titova N, Mestre TA (2020) Therapy of Parkinson\u2019s disease subtypes. Neurotherapeutics 17(4):1366\u20131377","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2520_CR123","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mds.27579","volume":"34","author":"P Martinez-Martin","year":"2019","unstructured":"Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K (2019) The long-term direct and indirect economic burden among Parkinson\u2019s disease caregivers in the United States. Movement Disord 34(2):236\u2013245","journal-title":"Movement Disord"},{"issue":"6","key":"2520_CR124","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.parkreldis.2015.03.024","volume":"21","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Ag\u00fcera-Ortiz L, Weintraub D, Riesco A, Kurtis MM, Chaudhuri KR (2015) Neuropsychiatric symptoms and caregiver\u2019s burden in Parkinson\u2019s disease. Parkinsonism Relat Disord 21(6):629\u2013634","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2520_CR125","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/mds.28912","volume":"37","author":"I Martinez-Valbuena","year":"2022","unstructured":"Martinez-Valbuena I, Visanji NP, Olszewska DA, Sousa M, Bhakta P, Vasilevskaya A, Anastassiadis C, Tartaglia MC, Kovacs GG, Lang AE (2022) Combining Skin \u03b1-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson\u2019s disease. Mov Disord 37(3):648\u2013650","journal-title":"Mov Disord"},{"key":"2520_CR126","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673893","volume":"12","author":"MJ Meinders","year":"2021","unstructured":"Meinders MJ, Gentile G, Schrag AE, Konitsiotis S, Eggers C, Taba P, Lorenzl S, Odin P, Rosqvist K, Chaudhuri KR, Antonini A, Bloem BR, Groot MM (2021) Advance care planning and care coordination for people with Parkinson\u2019s disease and their family caregivers-study protocol for a multicentre, randomized controlled trial. Front Neurol 12:673893","journal-title":"Front Neurol"},{"issue":"2","key":"2520_CR127","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JPD-202472","volume":"11","author":"TA Mestre","year":"2021","unstructured":"Mestre TA, Fereshtehnejad S-M, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodr\u00edguez-Violante M, Simuni T, Surmeier DJ, Weintraub D, McDermott MP, Lawton M, Marras C (2021) Parkinson\u2019s disease subtypes: critical appraisal and recommendations. J Parkinsons Dis 11(2):395\u2013404","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"2520_CR128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","volume":"20","author":"MG Miglis","year":"2021","unstructured":"Miglis MG, Adler CH, Antelmi E, Arnaldi D, Baldelli L, Boeve BF, Cesari M, Dall\u2019Antonia I, Diederich NJ, Doppler K, Du\u0161ek P, Ferri R, Gagnon J-F, Gan-Or Z, Hermann W, H\u00f6gl B, Hu MT, Iranzo A, Janzen A, Kuzkina A, Lee J-Y, Leenders KL, Lewis SJG, Liguori C, Liu J, Lo C, Ehgoetz Martens KA, Nepozitek J, Plazzi G, Provini F, Puligheddu M, Rolinski M, Rusz J, Stefani A, Summers RLS, Yoo D, Zitser J, Oertel WH (2021) Biomarkers of conversion to \u03b1-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol 20(8):671\u2013684","journal-title":"Lancet Neurol"},{"issue":"8","key":"2520_CR129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11910-013-0367-y","volume":"13","author":"JM Miyasaki","year":"2013","unstructured":"Miyasaki JM (2013) Palliative care in Parkinson\u2019s disease. Curr Neurol Neurosci Rep 13(8):367","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"2520_CR130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11910-015-0542-4","volume":"15","author":"JM Miyasaki","year":"2015","unstructured":"Miyasaki JM, Kluger B (2015) Palliative care for Parkinson\u2019s disease: has the time come? Curr Neurol Neurosci Rep 15(5):26","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"2520_CR131","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/mds.28773","volume":"37","author":"JM Miyasaki","year":"2022","unstructured":"Miyasaki JM, Lim S-Y, Chaudhuri KR, Antonini A, Piemonte M, Richfield E, Alburquerque Gonzalez D, Lorenzl S, Walker R, Bhidayasiri R, Bouca R, McConvey V (2022) Access and attitudes toward palliative care among movement disorders clinicians. Movement Disord 37(1):182\u2013189","journal-title":"Movement Disord"},{"issue":"5","key":"2520_CR132","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0891988717720302","volume":"30","author":"PE Mosley","year":"2017","unstructured":"Mosley PE, Moodie R, Dissanayaka N (2017) Caregiver burden in Parkinson disease: a critical review of recent literature. J Geriatr Psychiatry Neurol 30(5):235\u2013252","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"38","key":"2520_CR133","first-page":"627","volume":"113","author":"D Mo\u00dfhammer","year":"2016","unstructured":"Mo\u00dfhammer D, Haumann H, M\u00f6rike K, Joos S (2016) Polypharmacy-an upward trend with unpredictable effects. Deutsches Arzteblatt Int 113(38):627\u2013633","journal-title":"Deutsches Arzteblatt Int"},{"issue":"12","key":"2520_CR134","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Sim\u00f3n-S\u00e1nchez J, Schulte C, Sharma M, Krohn L, Pihlstr\u00f8m L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol J-C, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB, Adarmes-G\u00f3mez AD, Aguilar M, Aitkulova A, Akhmetzhanov V, Alcalay RN, Alvarez I, Alvarez V, Barrero FJ, Bergareche Yarza JA, Bernal-Bernal I, Billingsley K, Blazquez M, Bonilla-Toribio M, Bot\u00eda JA, Boungiorno MT, Brockmann K, Bubb V, Buiza-Rueda D, C\u00e1mara A, Carrillo F, Carri\u00f3n-Claro M, Cerdan D, Chelban V, Clarim\u00f3n J, Clarke C, Compta Y, Cookson MR, Craig DW, Danjou F, Diez-Fairen M, Dols-Icardo O, Duarte J, Duran R, Escamilla-Sevilla F, Escott-Price V, Ezquerra M, Feliz C, Fern\u00e1ndez M, Fern\u00e1ndez-Santiago R, Finkbeiner S, Foltynie T, Garcia C, Garc\u00eda-Ruiz P, Gomez Heredia MJ, G\u00f3mez-Garre P, Gonz\u00e1lez MM, Gonzalez-Aramburu I, Guelfi S, Guerreiro R, Hardy J, Hassin-Baer S, Hoenicka J, Holmans P, Houlden H, Infante J, Jes\u00fas S, Jimenez-Escrig A, Kaishybayeva G, Kaiyrzhanov R, Karimova A, Kinghorn KJ, Koks S, Kulisevsky J, Labrador-Espinosa MA, Leonard HL, Lewis P, Lopez-Sendon JL, Lovering R, Lubbe S, Lungu C, Macias D, Manzoni C, Mar\u00edn J, Marinus J, Marti MJ, Mart\u00ednez Torres I, Mart\u00ednez-Castrillo JC, Mata M, Mencacci NE, M\u00e9ndez-del-Barrio C, Middlehurst B, M\u00ednguez A, Mir P, Mok KY, Mu\u00f1oz E, Narendra D, Ojo OO, Okubadejo NU, Pagola AG, Pastor P, Perez Errazquin F, Peri\u00f1\u00e1n-Tocino T, Pihlstrom L, Plun-Favreau H, Quinn J, R\u2019Bibo L, Reed X, Rezola EM, Rizig M, Rizzu P, Robak L, Rodriguez AS, Rouleau GA, Ruiz-Mart\u00ednez J, Ruz C, Ryten M, Sadykova D, Schreglmann S, Shashkin C, Sierra M, Suarez-Sanmartin E, Taba P, Tabernero C, Tan MX, Tartari JP, Tejera-Parrado C, Tolosa E, Trabzuni D, Valldeoriola F, van Hilten JJ, van Keuren-Jensen K, Vargas-Gonz\u00e1lez L, Vela L, Vives F, Williams N, Zharkinbekova N, Zharmukhanov Z, Zholdybayeva E, Zimprich A, Ylikotila P, Reich S, Savitt J, Agee M, Alipanahi B, Auton A, Bell RK, Bryc K, Elson SL, Fontanillas P, Furlotte NA, Huber KE, Hicks B, Jewett EM, Jiang Y, Kleinman A, Lin K-H, Litterman NK, McCreight JC, McIntyre MH, McManus KF, Mountain JL, Noblin ES, Northover CA, Pitts SJ, Poznik GD, Sathirapongsasuti JF, Shelton JF, Shringarpure S, Tian C, Tung J, Vacic V, Wang X, Wilson CH, Anderson T, Bentley S, Dalrymple-Alford J, Fowdar J, Halliday G, Henders AK, Hickie I, Kassam I, Kennedy M, Kwok J, Lewis S, Mellick G, Montgomery G, Pearson J, Pitcher T, Sidorenko J, Silburn PA, Wallace L, Wray NR, Zhang F (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18(12):1091\u20131102","journal-title":"Lancet Neurol"},{"issue":"5","key":"2520_CR135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/jnc.14674","volume":"149","author":"MR Nichols","year":"2019","unstructured":"Nichols MR, St-Pierre M-K, Wendeln A-C, Makoni NJ, Gouwens LK, Garrad EC, Sohrabi M, Neher JJ, Tremblay M-E, Combs CK (2019) Inflammatory mechanisms in neurodegeneration. J Neurochem 149(5):562\u2013581","journal-title":"J Neurochem"},{"issue":"1","key":"2520_CR136","first-page":"28","volume":"11","author":"G Niewiadomska","year":"2021","unstructured":"Niewiadomska G, Niewiadomski W, Steczkowska M, Gasiorowska A (2021) Tau oligomers neurotoxicity. Life (basel, Switzerland) 11(1):28","journal-title":"Life (basel, Switzerland)"},{"key":"2520_CR137","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.656599","volume":"12","author":"GS Nuebling","year":"2021","unstructured":"Nuebling GS, Butzhammer E, Lorenzl S (2021) Assisted suicide in Parkinsonian disorders. Front Neurol 12:656599","journal-title":"Front Neurol"},{"key":"2520_CR138","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.parkreldis.2020.02.018","volume":"71","author":"O Okunoye","year":"2020","unstructured":"Okunoye O, Kojima G, Marston L, Walters K, Schrag A (2020) Factors associated with hospitalisation among people with Parkinson\u2019s disease - a systematic review and meta-analysis. Parkinsonism Relat Disord 71:66\u201372","journal-title":"Parkinsonism Relat Disord"},{"key":"2520_CR139","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002322","author":"D Oliver","year":"2020","unstructured":"Oliver D, Borasio GD, Veronese S, Voltz R, Lorenzl S, Hepgul N (2020) Current collaboration between palliative care and neurology: a survey of clinicians in Europe. BMJ Support Palliative Care. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002322","journal-title":"BMJ Support Palliative Care"},{"issue":"1","key":"2520_CR140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ene.12889","volume":"23","author":"DJ Oliver","year":"2016","unstructured":"Oliver DJ, Borasio GD, Caraceni A, de Visser M, Grisold W, Lorenzl S, Veronese S, Voltz R (2016) A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol 23(1):30\u201338","journal-title":"Eur J Neurol"},{"issue":"15","key":"2520_CR141","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.22826","volume":"24","author":"Y Osaki","year":"2009","unstructured":"Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP (2009) A validation exercise on the new consensus criteria for multiple system atrophy. Movement Disord 24(15):2272\u20132276","journal-title":"Movement Disord"},{"issue":"12","key":"2520_CR142","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s00415-016-8278-x","volume":"263","author":"E Owens","year":"2016","unstructured":"Owens E, Josephs KA, Savica R, Hassan A, Klassen B, Bower J, Maraganore D, Matsumoto J, Ahlskog JE (2016) The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol 263(12):2419\u20132423","journal-title":"J Neurol"},{"issue":"4","key":"2520_CR143","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","volume":"76","author":"E de Pablo-Fern\u00e1ndez","year":"2019","unstructured":"de Pablo-Fern\u00e1ndez E, Lees AJ, Holton JL, Warner TT (2019) Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76(4):470\u2013479","journal-title":"JAMA Neurol"},{"key":"2520_CR144","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.705407","volume":"12","author":"G Pagano","year":"2021","unstructured":"Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A (2021) A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s Disease (PASADENA): rationale, design, and baseline data. Front Neurol 12:705407","journal-title":"Front Neurol"},{"issue":"7","key":"2520_CR145","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares M, Rojo I, A, Manda G, Bosc\u00e1 L, Cuadrado A, (2020) Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells 9(7):1687","journal-title":"Cells"},{"issue":"9","key":"2520_CR146","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/mds.28624","volume":"36","author":"C Palleis","year":"2021","unstructured":"Palleis C, Brendel M, Finze A, Weidinger E, B\u00f6tzel K, Danek A, Beyer L, Nitschmann A, Kern M, Biechele G, Rauchmann B-S, H\u00e4ckert J, H\u00f6llerhage M, Stephens AW, Drzezga A, van Eimeren T, Villemagne VL, Schildan A, Barthel H, Patt M, Sabri O, Bartenstein P, Perneczky R, Haass C, Levin J, H\u00f6glinger GU (2021) Cortical 18 FPI-2620 binding differentiates corticobasal syndrome subtypes. Movement Disord 36(9):2104\u20132115","journal-title":"Movement Disord"},{"key":"2520_CR147","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105924","volume":"195","author":"C Palleis","year":"2020","unstructured":"Palleis C, Morenas-Rodriguez E, Murcia FJM, Giese A, Nuscher B, Haass C, H\u00f6glinger G, B\u00f6tzel K, Levin J (2020) Longitudinal correlation between neurofilament light chain and UMSARS in multiple system atrophy. Clin Neurol Neurosurg 195:105924","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"2520_CR148","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.parkreldis.2005.06.003","volume":"11","author":"S Papapetropoulos","year":"2005","unstructured":"Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash DC (2005) Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 11(7):459\u2013463","journal-title":"Parkinsonism Relat Disord"},{"key":"2520_CR149","doi-asserted-by":"crossref","unstructured":"Parkinson J (1817; 2002) An essay on the shaking palsy. 1817. J Neuropsychiatr Clin Neurosci 14(2):223\u201336; discussion 222","DOI":"10.1176\/jnp.14.2.223"},{"issue":"1","key":"2520_CR150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mdc3.13354","volume":"9","author":"C Peralta","year":"2022","unstructured":"Peralta C, Strafella AP, van Eimeren T, Ceravolo R, Seppi K, Kaasinen V, Arena JE, Lehericy S (2022) Pragmatic approach on neuroimaging techniques for the differential diagnosis of Parkinsonisms. Movement Disord Clin Pract 9(1):6\u201319","journal-title":"Movement Disord Clin Pract"},{"issue":"1","key":"2520_CR151","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000214","volume":"4","author":"MF Pereira","year":"2022","unstructured":"Pereira MF, Buchanan T, H\u00f6glinger GU, Bogdanovic M, Tofaris G, Prangnell S, Sarangmat N, FitzGerald JJ, Antoniades CA (2022) Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study. BMJ Neurol Open 4(1):e000214","journal-title":"BMJ Neurol Open"},{"issue":"2","key":"2520_CR152","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3233\/JPD-202332","volume":"11","author":"A P\u00e9rez-Soriano","year":"2021","unstructured":"P\u00e9rez-Soriano A, Giraldo DM, R\u00edos J, Mu\u00f1oz E, Compta Y, Mart\u00ed MJ (2021) Progression of motor and non-motor symptoms in multiple system atrophy: a prospective study from the Catalan-MSA registry. J Parkinsons Dis 11(2):685\u2013694","journal-title":"J Parkinsons Dis"},{"key":"2520_CR153","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2021.04.016","volume":"87","author":"A Pilotto","year":"2021","unstructured":"Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S, Turrone R, Gipponi S, Cottini E, Borroni B, Rizzetti MC, Pizzi M, Bonanni L, Sturchio A, Espay AJ, Zetterberg H, Ashton NJ, Hye A, Padovani A (2021) Plasma NfL, clinical subtypes and motor progression in Parkinson\u2019s disease. Parkinsonism Relat Disord 87:41\u201347","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"2520_CR154","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/mds.27964","volume":"35","author":"I Piot","year":"2020","unstructured":"Piot I, Schweyer K, Respondek G, Stamelou M, Sckopke P, Schenk T, Goetz CG, Stebbins GT, H\u00f6glinger GU (2020) The progressive supranuclear palsy clinical deficits scale. Movement Disord 35(4):650\u2013661","journal-title":"Movement Disord"},{"issue":"2","key":"2520_CR155","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2021","unstructured":"Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, Trenkwalder C, Sixel-D\u00f6ring F, Foubert-Samier A, Le Traon AP, Plazzi G, Biscarini F, Montplaisir J, Gagnon J-F, Postuma RB, Antelmi E, Meissner WG, Mollenhauer B, Ben-Shlomo Y, Hu MT, Parkkinen L (2021) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145(2):584\u2013595","journal-title":"Brain"},{"issue":"11","key":"2520_CR156","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","volume":"12","author":"RB Postuma","year":"2016","unstructured":"Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12(11):622\u2013634","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"2520_CR157","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Movement Disord 30(12):1591\u20131601","journal-title":"Movement Disord"},{"issue":"3","key":"2520_CR158","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma RB, Iranzo A, Hu M, H\u00f6gl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung K-Y, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon J-F, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A (2019) Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142(3):744\u2013759","journal-title":"Brain"},{"issue":"3","key":"2520_CR159","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00702-022-02464-x","volume":"129","author":"M P\u00f6tter-Nerger","year":"2022","unstructured":"P\u00f6tter-Nerger M, Dutke J, Lezius S, Buhmann C, Schulz R, Gerloff C, Kuhle J, Choe C-U (2022) Serum neurofilament light chain and postural instability\/gait difficulty (PIGD) subtypes of Parkinson\u2019s disease in the MARK-PD study. J Neural Transmission (vienna, Austria: 1996) 129(3):295\u2013300","journal-title":"J Neural Transmission (vienna, Austria: 1996)"},{"issue":"5","key":"2520_CR160","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3390\/jcm9051455","volume":"9","author":"T Prell","year":"2020","unstructured":"Prell T, Siebecker F, Lorrain M, Eggers C, Lorenzl S, Klucken J, Warnecke T, Buhmann C, T\u00f6nges L, Ehret R, Wellach I, Wolz M (2020a) Recommendations for standards of network care for patients with Parkinson\u2019s disease in Germany. J Clin Med 9(5):1455","journal-title":"J Clin Med"},{"issue":"8","key":"2520_CR161","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.3390\/jcm9082581","volume":"9","author":"T Prell","year":"2020","unstructured":"Prell T, Siebecker F, Lorrain M, T\u00f6nges L, Warnecke T, Klucken J, Wellach I, Buhmann C, Wolz M, Lorenzl S, Herbst H, Eggers C, Mai T (2020b) Specialized staff for the care of people with Parkinson\u2019s disease in Germany: an overview. J Clin Med 9(8):2581","journal-title":"J Clin Med"},{"key":"2520_CR162","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.parkreldis.2019.07.036","volume":"66","author":"SV Rabadia","year":"2019","unstructured":"Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J (2019) Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord 66:166\u2013170","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2520_CR163","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1212\/WNL.0000000000004078","volume":"89","author":"AH Rajput","year":"2017","unstructured":"Rajput AH, Rajput ML, Ferguson LW, Rajput A (2017) Baseline motor findings and Parkinson disease prognostic subtypes. Neurology 89(2):138\u2013143","journal-title":"Neurology"},{"issue":"16 Pt 2","key":"2520_CR164","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/01.wnl.0000285082.18969.3a","volume":"70","author":"AH Rajput","year":"2008","unstructured":"Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O (2008) Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 70(16 Pt 2):1403\u20131410","journal-title":"Neurology"},{"issue":"3","key":"2520_CR165","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/WNL.0b013e3181ae7af1","volume":"73","author":"AH Rajput","year":"2009","unstructured":"Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73(3):206\u2013212","journal-title":"Neurology"},{"issue":"5","key":"2520_CR166","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","volume":"10","author":"O Rascol","year":"2011","unstructured":"Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW (2011) A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10(5):415\u2013423","journal-title":"Lancet Neurol"},{"issue":"7803","key":"2520_CR167","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, Gradinaru V, Kampmann M, Kosik KS (2020) LRP1 is a master regulator of tau uptake and spread. Nature 580(7803):381\u2013385","journal-title":"Nature"},{"issue":"Suppl 1","key":"2520_CR168","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.parkreldis.2015.09.041","volume":"22","author":"G Respondek","year":"2016","unstructured":"Respondek G, H\u00f6glinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22(Suppl 1):S34\u2013S36","journal-title":"Parkinsonism Relat Disord"},{"key":"2520_CR169","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.644064","volume":"12","author":"G Respondek","year":"2021","unstructured":"Respondek G, H\u00f6glinger GU (2021) DescribePSP and ProPSP: German multicenter networks for standardized prospective collection of clinical data, imaging data, and biomaterials of patients with progressive supranuclear palsy. Front Neurol 12:644064","journal-title":"Front Neurol"},{"issue":"7","key":"2520_CR170","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mds.27034","volume":"32","author":"G Respondek","year":"2017","unstructured":"Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, M\u00fcller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol J-C, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, H\u00f6glinger GU (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Movement Disord 32(7):995\u20131005","journal-title":"Movement Disord"},{"key":"2520_CR171","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.irn.2019.10.003","volume":"149","author":"G Respondek","year":"2019","unstructured":"Respondek G, Stamelou M, H\u00f6glinger GU (2019) Classification of atypical Parkinsonism per pathology versus phenotype. Int Rev Neurobiol 149:37\u201347","journal-title":"Int Rev Neurobiol"},{"issue":"14","key":"2520_CR172","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","volume":"29","author":"G Respondek","year":"2014","unstructured":"Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, van Swieten JC, Troakes C, Al Sarraj S, Gelpi E, Gaig C, Tolosa E, Oertel WH, Giese A, Roeber S, Arzberger T, Wagenpfeil S, H\u00f6glinger GU (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Movement Disord 29(14):1758\u20131766","journal-title":"Movement Disord"},{"issue":"1","key":"2520_CR173","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mds.870090114","volume":"9","author":"M Richards","year":"1994","unstructured":"Richards M, Marder K, Cote L, Mayeux R (1994) Interrater reliability of the Unified Parkinson\u2019s disease rating scale motor examination. Movement Disord 9(1):89\u201391","journal-title":"Movement Disord"},{"issue":"4","key":"2520_CR174","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL (2018) CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90(4):e273\u2013e281","journal-title":"Neurology"},{"key":"2520_CR175","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101644","volume":"180","author":"TW R\u00f6sler","year":"2019","unstructured":"R\u00f6sler TW, Tayaranian Marvian A, Brendel M, Nyk\u00e4nen N-P, H\u00f6llerhage M, Schwarz SC, Hopfner F, Koeglsperger T, Respondek G, Schweyer K, Levin J, Villemagne VL, Barthel H, Sabri O, M\u00fcller U, Meissner WG, Kovacs GG, H\u00f6glinger GU (2019) Four-repeat tauopathies. Prog Neurobiol 180:101644","journal-title":"Prog Neurobiol"},{"issue":"1","key":"2520_CR176","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orr\u00f9 CD, Antelmi E, Mammana A, Hughson AG, Calandra-Buonaura G, Ladogana A, Plazzi G, Cortelli P, Caughey B, Parchi P (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140(1):49\u201362","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2520_CR177","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, Holguin B, Hughson AG, LaFontant D-E, Caspell-Garcia C, Coffey CS, Mollon J, Hutten SJ, Merchant K, Heym RG, Soto C, Caughey B, Kang UJ (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun 9(1):179","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"2520_CR178","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1212\/WNL.0000000000001715","volume":"85","author":"D Safarpour","year":"2015","unstructured":"Safarpour D, Thibault DP, DeSanto CL, Boyd CM, Dorsey ER, Racette BA, Willis AW (2015) Nursing home and end-of-life care in Parkinson disease. Neurology 85(5):413\u2013419","journal-title":"Neurology"},{"issue":"9","key":"2520_CR179","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/mds.28633","volume":"36","author":"G Saranza","year":"2021","unstructured":"Saranza G, Villanueva EQ, Lang AE (2021) Preferences for communication about end-of-life care in atypical Parkinsonism. Movement Disord 36(9):2116\u20132125","journal-title":"Movement Disord"},{"key":"2520_CR180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.05.016","volume":"75","author":"A Schrag","year":"2020","unstructured":"Schrag A, Hommel ALAJ, Lorenzl S, Meissner WG, Odin P, Coelho M, Bloem BR, Dodel R (2020) The late stage of Parkinson\u2019s -results of a large multinational study on motor and non-motor complications. Parkinsonism Relat Disord 75:91\u201396","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"2520_CR181","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, Gnjidic D, Del Mar CB, Roughead EE, Page A, Jansen J, Martin JH (2015) Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 175(5):827\u2013834","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2520_CR182","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12904-019-0433-6","volume":"18","author":"AA Seeber","year":"2019","unstructured":"Seeber AA, Pols AJ, Hijdra A, Grupstra HF, Willems DL, de Visser M (2019) Advance care planning in progressive neurological diseases: lessons from ALS. BMC Palliat Care 18(1):50","journal-title":"BMC Palliat Care"},{"key":"2520_CR02","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, Hu B, Schmeichel A, Singer W, Wu G, Tsai A-L, Shirani H, Nilsson KPR, Low PA, Soto C (2020) Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578:273\u2013277","journal-title":"Nature"},{"issue":"7880","key":"2520_CR183","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, Vidal R, Hallinan GI, Lashley T, Saito Y, Murayama S, Yoshida M, Tanaka H, Kakita A, Ikeuchi T, Robinson AC, Mann DMA, Kovacs GG, Revesz T, Ghetti B, Hasegawa M, Goedert M, Scheres SHW (2021) Structure-based classification of tauopathies. Nature 598(7880):359\u2013363","journal-title":"Nature"},{"issue":"6","key":"2520_CR184","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00415-019-09642-0","volume":"268","author":"C Simonet","year":"2021","unstructured":"Simonet C, Schrag A, Lees AJ, Noyce AJ (2021) The motor prodromes of parkinson\u2019s disease: from bedside observation to large-scale application. J Neurol 268(6):2099\u20132108","journal-title":"J Neurol"},{"issue":"6","key":"2520_CR185","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/ana.26089","volume":"89","author":"W Singer","year":"2021","unstructured":"Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Sletten DM, Gehrking TL, Gehrking JA, Olson AD, Suarez MD, Misra PP, Soto C, Low PA (2021) Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89(6):1212\u20131220","journal-title":"Ann Neurol"},{"issue":"12","key":"2520_CR186","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1007\/s00259-021-05391-3","volume":"48","author":"M Song","year":"2021","unstructured":"Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, Eckenweber F, Palleis C, Kaiser L, Finze A, Kern M, Nitschmann A, Biechele G, Katzdobler S, Bischof G, Hammes J, Jessen F, Saur D, Schroeter ML, Rumpf J-J, Rullmann M, Schildan A, Patt M, Neumaier B, Stephens AW, Rauchmann B-S, Perneczky R, Levin J, Classen J, H\u00f6glinger GU, Bartenstein P, Boening G, Ziegler S, Villemagne V, Drzezga A, Seibyl J, Sabri O, Brendel M (2021) Feasibility of short imaging protocols for 18FPI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging 48(12):3872\u20133885","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6645","key":"2520_CR187","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839\u2013840","journal-title":"Nature"},{"issue":"4","key":"2520_CR188","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ajpath.2013.12.007","volume":"184","author":"T Stewart","year":"2014","unstructured":"Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J (2014) Cerebrospinal fluid \u03b1-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184(4):966\u2013975","journal-title":"Am J Pathol"},{"issue":"40","key":"2520_CR189","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, Keutzer J, Mistry PK, Chandra SS (2017) Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-Associated Parkinson\u2019s disease. J Neurosci 37(40):9617\u20139631","journal-title":"J Neurosci"},{"issue":"9","key":"2520_CR190","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.3390\/jcm9092787","volume":"9","author":"J Tennigkeit","year":"2020","unstructured":"Tennigkeit J, Feige T, Haak M, Hellqvist C, Seven \u00dcS, Kalbe E, Schwarz J, Warnecke T, T\u00f6nges L, Eggers C, Loewenbr\u00fcck KF (2020) Structured care and self-management education for persons with parkinson\u2019s disease: why the first does not go without the second-systematic review, experiences and implementation concepts from Sweden and Germany. J Clin Med 9(9):2787","journal-title":"J Clin Med"},{"issue":"5","key":"2520_CR191","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s00415-018-8816-9","volume":"265","author":"A Tessitore","year":"2018","unstructured":"Tessitore A, Marano P, Modugno N, Pontieri FE, Tambasco N, Canesi M, Latorre A, Lopiano L, Sensi M, Quatrale R, Solla P, Defazio G, Melzi G, Costanzo AM, Gualberti G, Di Luzio PU, Antonini A (2018) Caregiver burden and its related factors in advanced Parkinson\u2019s disease: data from the PREDICT study. J Neurol 265(5):1124\u20131137","journal-title":"J Neurol"},{"issue":"3","key":"2520_CR192","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0091217418791460","volume":"54","author":"S Trapp","year":"2019","unstructured":"Trapp S, MacKenzie J, Gonzalez-Arredondo S, Rodriguez-Agudelo Y, Arango-Lasprilla JC (2019) Mediating role of caregiver burden among family caregivers of patients with Parkinson\u2019s disease in Mexico. Int J Psychiatry Med 54(3):203\u2013216","journal-title":"Int J Psychiatry Med"},{"issue":"6","key":"2520_CR193","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41556-021-00678-x","volume":"23","author":"D-JJ Truong","year":"2021","unstructured":"Truong D-JJ, Phlairaharn T, E\u00dfwein B, Gruber C, T\u00fcmen D, Balig\u00e1cs E, Armbrust N, Vaccaro FL, Lederer E-M, Beck EM, Geilenkeuser J, G\u00f6ppert S, Krumwiede L, Gr\u00e4tz C, Raffl G, Schwarz D, Zirngibl M, \u017divani\u0107 M, Beyer M, K\u00f6rner JD, Santl T, Evsyukov V, Strau\u00df T, Schwarz SC, H\u00f6glinger GU, Heutink P, Doll S, Conrad M, Giesert F, Wurst W, Westmeyer GG (2021) Non-invasive and high-throughput interrogation of exon-specific isoform expression. Nat Cell Biol 23(6):652\u2013663","journal-title":"Nat Cell Biol"},{"issue":"7","key":"2520_CR194","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.chembiol.2021.04.003","volume":"28","author":"F T\u00fcrker","year":"2021","unstructured":"T\u00fcrker F, Cook EK, Margolis SS (2021) The proteasome and its role in the nervous system. Cell Chem Biol 28(7):903\u2013917","journal-title":"Cell Chem Biol"},{"issue":"10","key":"2520_CR195","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.molmed.2020.03.012","volume":"26","author":"N Uemura","year":"2020","unstructured":"Uemura N, Uemura MT, Luk KC, Lee VM-Y, Trojanowski JQ (2020) Cell-to-cell transmission of tau and \u03b1-Synuclein. Trends Mol Med 26(10):936\u2013952","journal-title":"Trends Mol Med"},{"issue":"8","key":"2520_CR196","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/mds.23116","volume":"25","author":"SM van Rooden","year":"2010","unstructured":"van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J (2010) The identification of Parkinson\u2019s disease subtypes using cluster analysis: a systematic review. Movement Disord 25(8):969\u2013978","journal-title":"Movement Disord"},{"issue":"4","key":"2520_CR197","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, Dor\u00e9 V, Burnham SC, Masters CL, Rowe CC (2018) Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 14(4):225\u2013236","journal-title":"Nat Rev Neurol"},{"key":"2520_CR198","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.571800","volume":"12","author":"E Viscidi","year":"2021","unstructured":"Viscidi E, Litvan I, Dam T, Juneja M, Li L, Krzywy H, Eaton S, Hall S, Kupferman J, H\u00f6glinger GU (2021) Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol 12:571800","journal-title":"Front Neurol"},{"issue":"5","key":"2520_CR199","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00401-015-1483-3","volume":"130","author":"J Wagner","year":"2015","unstructured":"Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, Leonov A, Kleinknecht A, G\u00f6ricke B, Weishaupt JH, Weckbecker D, Reiner AM, Zinth W, Levin J, Ehninger D, Remy S, Kretzschmar HA, Griesinger C, Giese A, Fuhrmann M (2015) Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol 130(5):619\u2013631","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2520_CR200","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, B\u00e4hr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, B\u00f6tzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125(6):795\u2013813","journal-title":"Acta Neuropathol"},{"key":"2520_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29005","author":"GK Wenning","year":"2022","unstructured":"Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma J-A, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, H\u00f6glinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Movement Disord. https:\/\/doi.org\/10.1002\/mds.29005","journal-title":"Movement Disord"},{"issue":"4","key":"2520_CR202","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4161\/auto.7.4.14393","volume":"7","author":"AR Winslow","year":"2011","unstructured":"Winslow AR, Rubinsztein DC (2011) The Parkinson disease protein \u03b1-synuclein inhibits autophagy. Autophagy 7(4):429\u2013431","journal-title":"Autophagy"},{"issue":"3","key":"2520_CR203","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/geront\/26.3.260","volume":"26","author":"SH Zarit","year":"1986","unstructured":"Zarit SH, Todd PA, Zarit JM (1986) Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 26(3):260\u2013266","journal-title":"Gerontologist"},{"issue":"8","key":"2520_CR204","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3390\/jcm9082454","volume":"9","author":"MAS Zella","year":"2020","unstructured":"Zella MAS, Bartig D, Herrmann L, Respondek G, H\u00f6glinger G, Gold R, Woitalla D, Krogias C, T\u00f6nges L (2020) Hospitalization rates and comorbidities in patients with progressive supranuclear palsy in Germany from 2010 to 2017. J Clin Med 9(8):2454","journal-title":"J Clin Med"},{"issue":"3","key":"2520_CR205","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.26298","volume":"91","author":"H Zhang","year":"2022","unstructured":"Zhang H, Iranzo A, H\u00f6gl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel WH, Dauvilliers Y, Ju Y-E, Puligheddu M, Sonka K, Pelletier A, Montplaisir JY, Stefani A, Ibrahim A, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Janzen A, Figorilli M, Fantini ML, Postuma RB (2022a) Risk factors for phenoconversion in rapid eye movement sleep behavior disorder. Ann Neurol 91(3):404\u2013416","journal-title":"Ann Neurol"},{"issue":"2","key":"2520_CR206","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/mds.28847","volume":"37","author":"L Zhang","year":"2022","unstructured":"Zhang L, Cao B, Hou Y, Gu X, Wei Q, Ou R, Zhao B, Luo C, Shang H (2022b) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Movement Disord 37(2):421\u2013426","journal-title":"Movement Disord"},{"issue":"26","key":"2520_CR207","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2011196118","volume":"118","author":"S Zhang","year":"2021","unstructured":"Zhang S, Liu Y-Q, Jia C, Lim Y-J, Feng G, Xu E, Long H, Kimura Y, Tao Y, Zhao C, Wang C, Liu Z, Hu J-J, Ma M-R, Liu Z, Jiang L, Li D, Wang R, Dawson VL, Dawson TM, Li Y-M, Mao X, Liu C (2021) Mechanistic basis for receptor-mediated pathological \u03b1-synuclein fibril cell-to-cell transmission in Parkinson\u2019s disease. Proc Natl Acad Sci USA 118(26):e2011196118","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7802","key":"2520_CR208","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-020-2043-0","volume":"580","author":"W Zhang","year":"2020","unstructured":"Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, Murayama S, Ghetti B, Hasegawa M, Goedert M, Scheres SHW (2020) Novel tau filament fold in corticobasal degeneration. Nature 580(7802):283\u2013287","journal-title":"Nature"},{"issue":"9","key":"2520_CR209","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1017\/S1041610213000586","volume":"25","author":"M Zhong","year":"2013","unstructured":"Zhong M, Evans A, Peppard R, Velakoulis D (2013) Validity and reliability of the PDCB: a tool for the assessment of caregiver burden in Parkinson\u2019s disease. Int Psychogeriatr 25(9):1437\u20131441","journal-title":"Int Psychogeriatr"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-022-02520-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T21:36:15Z","timestamp":1727386575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-022-02520-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":211,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2520"],"URL":"https:\/\/doi.org\/10.1007\/s00702-022-02520-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}